Reports Q4 revenue $19.3M, consensus $18.27M. “Our performance throughout 2023 consistently demonstrated the success of our focused U.S. commercial strategy and our ability to further expand access to our Zephyr Valve treatment within our substantial addressable patient population. Our success, particularly in the U.S., leaves us confident that our business is better positioned than ever for long-term, sustainable growth,” said Glen French, CEO. “In 2024, we look forward to further expanding and strengthening our account base.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LUNG:
- Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
- Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
- Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
